Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study

被引:4
|
作者
O'Hara, Montana [1 ,2 ]
Janda, Monika [3 ]
McCarthy, Alexandra L. [4 ,5 ]
Nicklin, James [1 ]
Walker, Graeme [6 ]
Obermair, Andreas [1 ,2 ]
机构
[1] Royal Brisbane & Womens Hosp, Queensland Ctr Gynaecol Canc, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Clin Res, Brisbane, Qld, Australia
[3] Univ Queensland, Fac Med, Ctr Hlth Serv Res, Brisbane, Qld, Australia
[4] Univ Queensland, Sch Nursing Midwifery & Social Work, Brisbane, Qld, Australia
[5] Mater Res Inst, Brisbane, Qld, Australia
[6] Gold Coast Univ Hosp, Southport, Qld, Australia
来源
基金
英国医学研究理事会;
关键词
Endometrial cancer; Levonorgestrel intrauterine device; Progestin; progesterone; Decision-making; Patient experience; OBESITY; WOMEN; RISK; MANAGEMENT; PERCEPTIONS; PREVENTION; KNOWLEDGE; OUTCOMES; THERAPY;
D O I
10.1016/j.gore.2021.100914
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The aim of the study was to obtain an in-depth understanding of the experience of women who received non-surgical treatment for endometrial adenocarcinoma (EAC) or endometrial hyperplasia with atypia (EHA). Enhanced understanding of women's experiences of non-surgical treatment is essential to inform counselling of the growing number of patients in this field. Methods: Individual semi-structured interviews were conducted with 21 women who received conservative (nonsurgical hormonal) treatment for early stage EAC or EHA using the levonorgestrel intrauterine device (LNG-IUD) as part of the feMMe trial (NCT01686126). All interviews were audiotaped and transcribed verbatim prior to content analysis. Results: Of the 21 women interviewed, ten received conservative treatment for early stage EAC and 11 received conservative treatment for EHA. Five overarching themes were identified: i) extensive information and support needs (e.g. understanding of how the LNG-IUD treatment worked); ii) gratitude for treatment choice and nonsurgical options (e.g. avoidance of potential risks associated with surgery); iii) onco-fertility (e.g. desire to maintain reproductive potential); iv) patient experience of overweight and obesity related to EAC development (e.g. history of trauma and disordered eating, multiple unsuccessful weight loss attempts); and v) patient experience of treatment options and actual non-surgical treatment (e.g. desire for early referral to counselling services). Conclusions: This qualitative investigation enabled novel insights into the treatment preferences and decisionmaking process of women with newly diagnosed EHA and EAC when offered non-surgical treatment options. These insights facilitate the development of pragmatic guidance and decision support tools that could be tested in future clinical trials.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia
    Campo, Giovanni
    Rebecchi, Agnese
    Vanni, Valeria S.
    Pagliardini, Luca
    Patruno, Carola
    Papaleo, Enrico
    Candiani, Massimo
    Giardina, Paolo
    REPRODUCTIVE BIOMEDICINE ONLINE, 2021, 43 (05) : 864 - 870
  • [42] Intrauterine progesterone treatment of early endometrial cancer
    Montz, FJ
    Bristow, RE
    Bovicelli, A
    Tomacruz, R
    Kurman, RJ
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (04) : 651 - 657
  • [43] Effect of the Levonorgestrel-Releasing Intrauterine System on the Uterine Artery, Uterine Volume, and Endometrium in Endometrial Hyperplasia without Atypia
    Yuksel, Ilkbal Temel
    Erdem, Baki
    Cetin, Berna Aslan
    Koroglu, Nadiye Dugan
    Dansuk, Ramazan
    JOURNAL OF ACADEMIC RESEARCH IN MEDICINE-JAREM, 2019, 9 : S15 - S18
  • [45] Risk for Advanced-Stage Endometrial Cancer in Surgical Specimens from Patients with Complex Endometrial Hyperplasia with Atypia
    Eddib, Abeer
    Allaf, Baraa
    Lee, Jenny
    Yeh, John
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2012, 73 (01) : 38 - 42
  • [46] Endometrial vascularization in levonorgestrel intrauterine device users; computerized microvessel measurement study
    Jondet, M
    Letellier, B
    Verdys, MT
    CONTRACEPTION, 2005, 71 (01) : 60 - 64
  • [47] The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: An Australian study and systematic review
    Buttini, Melissa J.
    Jordan, Susan J.
    Webb, Penelope M.
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2009, 49 (03): : 316 - 322
  • [48] Conservative management of endometrial hyperplasia/carcinoma with levonorgestrel intrauterine system may be less effective in patients with morbid obesity
    Graul, A.
    Haggerty, A. F.
    Reed, H.
    Kim, S. H.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 152 - 152
  • [49] Treatment of dysfunctional uterine bleeding: Patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy
    Bourdrez, P
    Bongers, MY
    Mol, BWJ
    FERTILITY AND STERILITY, 2004, 82 (01) : 160 - 166
  • [50] Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
    Graul, Ashley
    Wilson, Elise
    Ko, Emily
    Haggerty, Ashley F.
    Reed, Helen
    Koelper, Nathanael
    Kim, Sarah H.
    GYNECOLOGIC ONCOLOGY REPORTS, 2018, 26 : 45 - 48